Novartis is pushing the boundaries of innovation with bold science, seeking to transform lives and striving toward cures for patients.
Novartis Oncology at Medical Meetings
Reimagining Breast Cancer
For more than 30 years, Novartis’ priority has been to deliver innovative targeted therapies for breast cancer that extend and transform patients’ lives as we work towards a cure.
Reimagining Outcomes in Prostate Cancer with Phenotypic Precision Medicine
Novartis is committed to exploring the full potential of radioligand therapy, one of our four therapeutic platforms, to transform patients’ lives. We are using bold science to research and develop new targeted treatments that address critical unmet needs in advanced prostate cancer.
Researching Multiple Approaches to Improving the Treatment Landscape for Patients with Lung Cancer
Worldwide, more people still die every year from lung cancer than from any other cancer. Bold science is urgently needed to help those living with lung cancer. From exploring targeted therapies, to the role interleukin-1 beta (IL-1β) may play in pro-tumor inflammation in lung cancer, and to potential new immuno- and radioligand treatments, our aspiration is to deliver potentially transformative medicines in lung cancer.
Novartis has a legacy of pursuing bold scientific approaches to solve serious challenges, from cancer to rare diseases. Now, we are striving to transform the lives of those affected by PIK3CA-Related Overgrowth Spectrum (PROS), a group of rare and potentially debilitating conditions.
Targeting Advanced Melanoma
As the established leader in targeted therapy for BRAF+ advanced melanoma, Novartis is proud to have played a role in reimagining the care of this life-threatening cancer. We have helped to transform the lives of nearly 200 000 people living with melanoma, and we remain dedicated to advancing science behind our targeted therapies to give patients the best chance for extended survival.
Bold Bets for the Future
Driven by our passion for patients and grounded in our industry-leading oncology pipeline of more than 45 different compounds across 70+ development programs, we’re rapidly advancing novel treatment approaches in areas of great medical need, including melanoma, lung, and pancreatic cancer.
Stay up-to-date on Novartis Oncology news and stories.
With the approval of a breakthrough treatment 20 years ago, Novartis helped pioneer a new era in the care of chronic myeloid leukemia (CML), while opening the door to reimagine possibilities for other forms of cancer and blood diseases.
Today, our research continues, seeking to address remaining unmet needs for patients with CML.
Reimagining MDS & AML
We are taking a bold approach with our research of TIM-3, an immune target specific to myeloid malignancies that has the potential to reawaken the immune system to selectively attack leukemic stem cells, the source of myelodysplastic syndromes and acute myeloid leukemia.
To transform the treatment of these cancers, our goal is to deliver the first immune-myeloid therapy that has the potential to provide durable responses without added toxicity.
Reimagining Care with CAR-T
Cancer care was revolutionized with the first FDA approval of CAR-T cell therapy. Our collaboration with industry-leading partners made the “quantum leap” of what was once a research theory into a reality for patients with certain advanced B-cell blood cancers across the globe.
Our focus is to broaden the impact of cell & gene therapies by diving deeper into B-cell malignancies and reaching more patients in other hematological cancers.
From Cancer to Cures
Our new monthly series "Let's Talk About the C Word: From Cancer to Cures" featuring President of Novartis Oncology Dr. Susanne Schaffert, addresses challenging cancer related topics.
Novartis is deeply committed to transforming the lives of people living with blood cancers and serious life-threatening blood disorders. We believe that anyone living with these conditions has the right to a life free from pain, free from symptoms and free from disease – this is our vision for the future.
Reimagining Sickle Cell Disease
For years, Novartis has been committed to understanding sickle cell disease (SCD) and developing effective treatments. From advances in innovative chronic therapies targeting vaso-occlusive crises – the hallmark of and greatest unmet need in the disease – to the promise of innovative gene therapy, Novartis is continually seeking new approaches to manage and treat SCD.
We are equally committed to expanding access to diagnosis and treatment across the globe, as well as providing comprehensive support to patients, health care providers and caregivers to end health care disparities.
When science and passion connect, innovation happens. Join us.
- Qualified Person & Quality Assurance Manager
- Oncology Sales Specialist - Prostate Cancer – ALBUQUERQUE, NM - Remote
Albuquerque, NM, USA
- Director, Data Quality
East Hanover, NJ, USA
- Clinical Data Analyst
Carlsbad, CA, USA